Small Intestinal Bacterial Overgrowth (SIBO)

Condition: SIBO (Small Intestinal Bacterial Overgrowth)  |  Category: Gut and Digestive Health  |  Reviewed by: Brian Lamkin, DO

What Is SIBO?

Small intestinal bacterial overgrowth (SIBO) is a condition in which bacteria that normally inhabit the colon colonize the small intestine in abnormally large numbers. The small intestine is designed for efficient nutrient absorption with relatively low bacterial density. When bacteria establish in this environment, they ferment carbohydrates before absorption, producing hydrogen and methane gas that causes bloating, pain, and altered bowel habits while simultaneously damaging the absorptive mucosa and competing for nutrients.

SIBO is present in an estimated 50 to 78 percent of patients diagnosed with irritable bowel syndrome, making it the most commonly missed treatable cause of functional digestive symptoms. Two primary types produce distinct clinical pictures: hydrogen-dominant SIBO (bacterial fermentation producing diarrhea and bloating) and methane-dominant SIBO (methanogenic archaea producing constipation through smooth muscle relaxation). The gas type guides treatment selection because the organisms and mechanisms differ.

Why SIBO Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

SIBO develops when the mechanisms that normally maintain low bacterial density in the small intestine are impaired. Identifying which mechanism has failed determines both treatment and recurrence prevention.

Migrating Motor Complex Dysfunction

The MMC is a cyclic electrical and mechanical pattern that sweeps the small intestine clean every 90 to 120 minutes between meals. It is suppressed by frequent eating, narcotics, anticholinergic medications, and autonomic nervous system dysfunction. Post-infectious IBS from acute gastroenteritis damages the MMC through anti-CdtB and anti-vinculin autoantibodies that target the nerve cells governing the MMC. This is the most common mechanism and the most important target for recurrence prevention.

Reduced Gastric Acid and Motility Impairment

Gastric acid normally sterilizes ingested food, preventing oral and gastric bacteria from colonizing the small intestine. PPI use and hypochlorhydria remove this sterilizing barrier. Hypothyroidism slows intestinal motility and creates the static environment favorable for bacterial overgrowth. Structural abnormalities including strictures, adhesions, and blind loops from prior surgery create stagnant zones where bacteria accumulate.

Ileocecal Valve Dysfunction and Systemic Conditions

The ileocecal valve normally prevents reflux of colonic bacteria into the small intestine. Dysfunction allows colonic bacteria continuous access to the small intestinal environment. Systemic conditions including thyroid dysfunction, diabetes with autonomic neuropathy, scleroderma, and chronic stress reducing vagal tone all create SIBO-favorable conditions.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The recurrent SIBO patient treated repeatedly without recurrence prevention: three courses of rifaximin over 4 years, each producing 3 to 6 months of improvement before relapse. No post-treatment prokinetic prescribed. No root cause identified. Adding low-dose erythromycin prokinetic and implementing meal spacing allowed 12-month sustained remission.
• The methane-SIBO constipation patient treated with rifaximin alone: constipation-predominant SIBO with methane peak of 28 ppm. Treated with rifaximin alone on two prior occasions with minimal improvement. Adding neomycin produced dramatically superior treatment response because archaea driving methane were not covered by prior treatment.
• The post-food-poisoning IBS patient: developed IBS-D following Campylobacter infection 3 years prior. Breath test positive for hydrogen. This is post-infectious SIBO from autoimmune MMC damage. Treatment plus sustained prokinetic therapy addresses both overgrowth and underlying motility dysfunction.
• The hypothyroid SIBO patient: recurrent SIBO episodes correlating with periods of undertreated hypothyroidism. Thyroid optimization reduces gut transit time and MMC suppression. SIBO recurrence dramatically reduces when free T3 is maintained in the upper third of the reference range.

Treatment and Optimization Strategy

Two-Phase Protocol: Eradication Then Prevention

What Most Doctors Miss

• Post-treatment prokinetic therapy is almost never prescribed: the most consistent predictor of SIBO recurrence is impaired MMC function. Restoring the MMC through prokinetic therapy and meal spacing is systematically absent from standard management.
• Methane-dominant SIBO requires neomycin, not rifaximin alone: methane is produced by archaea, not bacteria. Rifaximin does not cover archaea. Patients treated with rifaximin alone for methane-dominant SIBO receive an antibiotic that does not target the organism producing their symptom.
• Post-infectious SIBO from MMC autoimmune damage is not identified: anti-CdtB and anti-vinculin antibodies are the most common missed diagnosis in recurrent SIBO. Without identification, the autoimmune motility driver produces recurrence regardless of eradication courses.
• Nutritional consequences are not assessed: B12, iron, and fat-soluble vitamin depletion from bacterial competition and malabsorption are predictable, measurable consequences almost never evaluated alongside SIBO diagnosis.

When to Seek Medical Care

Bloating that worsens through the day and improves overnight, gas and abdominal discomfort triggered by carbohydrates and fiber, or IBS symptoms that have persisted despite dietary modification all warrant SIBO breath testing before indefinite dietary restriction is continued.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches SIBO

At The Lamkin Clinic, SIBO evaluation includes breath testing with both hydrogen and methane gas measurement, nutritional markers including B12, iron, and vitamin D, thyroid function, and comprehensive stool analysis. Treatment follows a two-phase eradication-then-prevention protocol with the specific antibiotic or herbal combination matched to the gas type and prokinetic therapy prescribed to prevent recurrence.

Related Conditions

Related Symptoms